Cited by 615Growth Hormone and Insulin-like Growth FactorsPituitary Gland Disorders and TreatmentsHormonal and reproductive studies

Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia

Ho, Ken K Y, _, _·2007·European Journal of Endocrinology

Abstract

Objective: The GH Research Society held a Consensus Workshop in Sydney, Australia, 2007 to incorporate the important advances in the management of GH deficiency (GHD) in adults, which have taken place since the inaugural 1997 Consensus Workshop. Method: Two commissioned review papers, previously published Consensus Statements of the Society and key questions were circulated before the Workshop, which comprised a rigorous structure of review with breakout discussion groups. A writing group transcribed the summary group reports for drafting in a plenary forum on the last day. All participants were sent a polished draft for additional comments and gave signed approval to the final revision. Conclusion: Testing for GHD should be extended from hypothalamic–pituitary disease and cranial irradiation to include traumatic brain injury. Testing may indicate isolated GHD; however, idiopathic isolated GHD occurring de novo in the adult is not a recognized entity. The insulin tolerance test, combined administration of GHRH with arginine or growth hormone-releasing peptide, and glucagon are validated GH stimulation tests in the adult. A low IGF-I is a reliable diagnostic indicator of GHD in the presence of hypopituitarism, but a normal IGF-I does not rule out GHD. GH status should be reevaluated in the transition age for continued treatment to complete somatic development. Interaction of GH with other axes may influence thyroid, glucocorticoid, and sex hormone requirements. Response should be assessed clinically by monitoring biochemistry, body composition, and quality of life. There is no evidence that GH replacement increases the risk of tumor recurrence or de novo malignancy.

Integrity signals

Registry

Crossref · 10.1530/eje-07-0631

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GHD has a wide range of test methodology and diagnostic thresholds employed across studies, despite agreement among global guidelines as to what constitutes deficiency.

    “GHD in particular has a wide range of test methodology and diagnostic thresholds employed across studies, despite agreement among global guidelines [26 · , 64-67] as to what constitutes deficiency.”

    From Neuroendocrine Disruptions Following Head Injury (2023) · cites this paper as [64]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ho, K. K. Y., & _, _.
Affiliations
Garvan Institute of Medical Research (AU)
Venue
European Journal of Endocrinology
Published
2007-12
Volume
157
Issue
6
Pages
695-700
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2130988832
Cited by
615
References
1
Citations by year
2026: 6 · 2025: 18 · 2024: 21 · 2023: 22 · 2022: 34 · 2021: 32 · 2020: 29 · 2019: 23 · 2018: 23 · 2017: 31 · 2016: 40 · 2015: 35 · 2014: 43 · 2013: 40 · 2012: 49
FWCI
28.12
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
adult growth hormone deficiency, growth hormone replacement therapy, GH stimulation test, insulin tolerance test, growth hormone-releasing peptide, glucagon stimulation test, insulin-like growth factor I, hypopituitarism, traumatic brain injury, hypothalamic-pituitary disease, cranial irradiation, treatment response monitoring, cancer recurrence risk, de novo malignancy
MeSH terms
Adult, Aged, Arginine, Brain Injuries, Female, Glucagon, Humans, Hypopituitarism, Insulin-Like Growth Factor I, Male, Growth Hormone-Releasing Hormone, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review